Cediranib

Product Description

Cediranib is a highly potent and ATP-competitive inhibitor of VEGFR2 (IC₅₀ = <1 nM). Cediranib also potently inhibits PDGFR1, VEGFR3, VEGFR1, c-Kit, PDGFR2 and FGFR1 (IC₅₀ values are 2, 3, 5, 5, 26 and 36 nM, respectively), and inhibits CSF-1R, Src, and Abl (IC₅₀ values are 110, 130 and 260 nM, respectively). Cediranib induces hypoxia, prevents VEGF-induced angiogenesis and suppresses homology-directed DNA repair (HDR) factors BRCA1/2 and RAD51. Cediranib decreases cell motility, proliferation and cell viability. Cediranib is active in vivo.

Solubility

Preparing Stock Solutions for Cediranib

The following data is based on the product molecular weight 450.51

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.22 mL	11.10 mL	22.20 mL
5 mM	0.44 mL	2.22 mL	4.44 mL
10 mM	0.22 mL	1.11 mL	2.22 mL
50 mM	0.04 mL	0.22 mL	0.44 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Kaplan Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci.Transl.Med. 2019 PMID: 31092693
• Momeny Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells Eur.J.Pharmacol. 2020 PMID: 32593665
• Wedge AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005 PMID: 15899831